EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Deinove's enterprise value is €6.19 Mil.
Deinove's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was €-7.30 Mil. Therefore, Deinove's EV-to-EBITDA for today is -0.85.
The historical rank and industry rank for Deinove's EV-to-EBITDA or its related term are showing as below:
XPAR:ALDEI's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.15 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-05), Deinove's stock price is €0.0265.
Deinove's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was €-0.240. Therefore, Deinove's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Deinove EV-to-EBITDA Historical Data
The historical data trend for Deinove's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Deinove's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Deinove's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Deinove's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Deinove's EV-to-EBITDA falls into.
Deinove EV-to-EBITDA Calculation
Deinove's EV-to-EBITDA for today is calculated as:
Deinove's current Enterprise Value is €6.19 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Deinove's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was €-7.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Deinove (XPAR:ALDEI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Deinove's share price for today is €0.0265.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Deinove's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was €-0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Deinove's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Deinove SA is a biotechnology company engaged in the development of technologies and molecules for the health, nutrition and cosmetics industries. It is developing in two areas of activity, New-generation anti-infective ANTIBIOTICS which involves the search for novel anti-infective molecules and the development of new generations of drugs capable of responding to the challenges of antibiotic resistance; and BIOACTIVES, natural active ingredients discovers, develops and produces bioactives, active ingredients of natural origin from its bacterial biodiversity bank, to invent the new generation of sustainable cosmetics and intends to quickly bring its know-how and its products to other fields, such as nutrition and health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XPAR:ALDEI has been successfully added to your 